Riskpilot← Back to searchSign inGet full accessMedlivus AB
ABActiveOrg 5568774227Mogatan 45Engineering activities and related technical consultancy · NACE 7112Est. 20110 employees
Revenue 2024
SEK 37K
-1875050% vs 2023
EBITDA margin
67.1%
+256% vs 2023
Equity ratio
2.3%
Financial strength
Net profit 2024
SEK 21K
+224% vs 2023
| Revenue | SEK 37K | -1875050% |
| EBITDA | SEK 25K | +256% |
| Net profit | SEK 21K | +224% |
| Total assets | SEK 63K | +111% |
| Equity | SEK 1K | +107% |
| Employees | 0 | — |
Legal name
Medlivus AB
Org number
5568774227
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
20 december 2011
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva verksamhet i form av tjänster, undervisning, konsultativ och teknisk innovativ verksamhet inom medicin samt medicinsk- och annan vetenskapsjournalistisk verksamhet. Bolaget ska också äga och förvalta fastigheter och värdepapper samt därmed förenlig verksamhet.
Address
Mogatan 45
Email
anders.olsson85@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 204 | 0 | −0 | 37 |
| Staff expenses | — | — | −2 | −0 | — |
| EBITDA | −7 | 195 | −14 | −16 | 25 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −7 | 195 | −14 | −16 | 25 |
| Net financials | — | — | — | −1 | — |
| Profit before tax | −7 | 195 | −14 | −17 | 25 |
| Tax | −0 | −40 | — | — | −4 |
| Net profit | −7 | 155 | −14 | −17 | 21 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 43 | 288 | 86 | 30 | 63 |
| Equity | 43 | 199 | −3 | −20 | 1 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 0 | 90 | 89 | 50 | 62 |
| Total debt | — | 90 | 89 | 50 | 62 |
EBITDA margin
67.1%
This company
15.8%
Market median
+325% vs market
20202024
Equity ratio
2.3%
This company
38.2%
Market median
-94% vs market
20202024
Return on equity
1487.1%
This company
18.4%
Market median
+7982% vs market
20202024
Net profit margin
57.0%
This company
8.1%
Market median
+604% vs market
20202024
Asset turnover
0.59×
This company
1.12×
Market median
-47% vs market
20202024
Debt / equity
43.01×
This company
0.62×
Market median
-6837% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (3) | ||
| Board of Directors | 2020 – 2020 | |
| Chairman | 2020 – 2020 | |
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medlivus AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Tord Olsson | Board of Directors | 0 companies |
| Kurt Lennart Sjölén | Board of Directors | 0 companies |
| Julia Maria Sjölén | Chairman | 0 companies |
| Klara Linnéa Sjölén | Deputy Board Member | 0 companies |
| Ann-Mari Sjölén | Deputy Board Member | 0 companies |